Janux Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
JANX$12.76-27.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except share and par value data)
| December 31, | ||
|---|---|---|
| Assets | 2023 | 2022 |
| Current assets: | ||
| Cash and cash equivalents | $19,205 | $51,426 |
| Short-term investments | 324,823 | 275,590 |
| Prepaid expenses and other current assets | 5,213 | 5,423 |
| Total current assets | 349,241 | 332,439 |
| Restricted cash | 816 | 816 |
| Property and equipment, net | 7,003 | 7,086 |
| Operating lease right-of-use assets | 20,838 | 22,279 |
| Other long-term assets | 2,509 | 1,390 |
| Total assets | $380,407 | $364,010 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,424 | $2,159 |
| Accrued expenses | 7,387 | 8,179 |
| Current portion of deferred revenue | 1,705 | 5,406 |
| Current portion of operating lease liabilities | 1,517 | 763 |
| Total current liabilities | 13,033 | 16,507 |
| Deferred revenue, net of current portion | — | 2,221 |
| Operating lease liabilities, net of current portion | 23,025 | 24,542 |
| Total liabilities | 36,058 | 43,270 |
| Commitments and contingencies (Note 3) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; authorized shares – 10,000,000 at December 31, 2023 and 2022, respectively; no shares issued and outstanding at December 31, 2023 and 2022 | — | — |
| Common stock, $0.001 par value; authorized shares – 200,000,000 at December 31, 2023 and 2022, respectively; issued shares – 46,262,759 and 41,684,666 at December 31, 2023 and 2022, respectively; outstanding shares – 46,252,440 and 41,616,260 at December 31, 2023 and 2022, respectively | 46 | 42 |
| Additional paid-in capital | 512,401 | 432,703 |
| Accumulated other comprehensive income (loss) | 665 | (1,535) |
| Accumulated deficit | (168,763) | (110,470) |
| Total stockholders’ equity | 344,349 | 320,740 |
| Total liabilities and stockholders’ equity | $380,407 | $364,010 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.